HWHG(SH:600079) Bei Jing Shang Bao·2025-12-12 13:06Core Viewpoint - Humanwell Healthcare (人福医药) has received a pre-penalty notice from the Hubei Securities Regulatory Bureau, revealing illegal activities that may result in a total fine of 17.5 million yuan, alongside other risk warnings for the company [2][6]. Group 1: Illegal Activities - Humanwell Healthcare and its controlling shareholder, Dongdai Group (当代集团), are implicated in four illegal activities, including failure to disclose non-operating fund occupation and significant omissions in annual reports for 2020 and 2022 [3][4]. - From 2020 to March 2022, Humanwell Healthcare had a cumulative non-operating fund occupation of 12.785 billion yuan with Dongdai Group, which was not disclosed as required [3][4]. - Humanwell Healthcare's annual reports for 2020, 2021, and the first half of 2022 contained false records, leading to inflated net profits of 143 million yuan, 72 million yuan, and 91 million yuan respectively [4][5]. Group 2: Penalties and Consequences - The Hubei Securities Regulatory Bureau plans to impose a fine of 8.5 million yuan on Humanwell Healthcare and a 9 million yuan fine on Dongdai Group, with additional warnings issued to the company's former chairman and board members [6][7]. - Humanwell Healthcare's stock will be subject to risk warnings and will be suspended for one day on December 15, with risk warnings starting December 16 [6][7]. - Ai Luming, the head of Dongdai Group, faces a seven-year market ban due to his central role in the illegal activities related to Humanwell Healthcare [6][7]. Group 3: Company Background and Changes - Humanwell Healthcare is a leading pharmaceutical company in Hubei, focusing on areas such as neurological drugs and steroid hormones [2]. - As of August this year, Humanwell Healthcare has undergone a change in control, with the new controlling entity being China Merchants Group, effectively severing ties with Dongdai Group [7].